Used in the treatment of autoimmune and inflammatory diseases, particularly in targeting pathways involved in conditions like lupus and rheumatoid arthritis. It neutralizes the activity of CXCL10 (IP-10), a chemokine that attracts immune cells to sites of inflammation, thereby reducing immune-mediated tissue damage. Investigated in clinical trials for its potential to modulate excessive immune responses, especially in patients unresponsive to conventional therapies. Also utilized as a reference standard in immunoassay development and biosimilar characterization to ensure consistency and efficacy in therapeutic antibody production.